Articles On Race Oncology (ASX:RAC)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Highlights ASX 200 and small caps show steady gains Mining and energy sectors capture attention Key project expansions in Australia and abroad Overview of ASX 200 and Small-Cap Movements The ASX stock market saw modest gains as t...

Highlights International Graphite progresses land acquisition for a commercial graphite micronising plant in Western Australia. Recce Pharmaceuticals gains a key Hong Kong patent, strengthening protection for its anti-infective drug ca...

ASX shrugs off hot CPI read, closes up 0.81% Gold, lithium, rare earths lead resources gains Broad upward momentum across eight sectors   Gold and lithium build momentum Lion Selection Group (ASX:LSX) MD Hedley Widdup predicted Australia...

Race Oncology achieves ethics approval for HARNESS-1 Phase 1a/b trial of RC220 with osimertinib in adults with EGFR-mutant non-small cell lung cancer Ethics approval allows lead clinical site Monash Health to start enrolling patients subje...

Anti-infectives house Firebrick Pharma reveals what shareholders think of the company – warts and all Pot play Vitura blooms in the September quarter Recce claims early victory in war against superbugs   In the spirit of being truthful a...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.6% to 8,590.6 points. Four ASX shares that have failed to follow the market higher today are...

ASX health sector fell 1.8% for the week, while broader market dropped 3.86% in the same period  FDA confirms Animal Rule and PRV potential for Island Pharmaceutical’s Galidesivir in Marburg Clever Culture identifies more than $45 million...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

Good afternoon and welcome to HotCopper’s Market Close for Tuesday of Week 47, I’m Jon Davidson. After Wall Street posted its worst day in a month overnight, no surprise the ASX followed suit with our tech index down over -6% in the final h...

Host Tylah Tully chats to Race Oncology (ASX:RAC) CEO Dr Daniel Tillett to unpack two major new clinical programs for RC220 in lung cancer and AML. He explains the scientific breakthrough that revealed how RC220 truly works, why its dual an...

ASX resists session lows of -0.53pc to close 0.02pc higher Info tech, energy, real estate lead gains Banks and finance stocks in retreat ASX recovers from session lows The ASX 200 started the day in the red and stayed there until the las...

R220’s unique molecular mechanism of action opens major clinical and commercial opportunities RAC expanding clinical activities to include Acute Myeloid Leukaemia and non-small cell lung cancer trials Continued clinical focus on cardiopro...

Race Oncology (ASX:RAC) has sought to expand the total addressable markets it can reach with its cancer drug RC220, on Monday launching a Phase Three Acute Myeloid Leukemia (AML) trial, “bridging RC110 to RC220 providing a… low-cost pathway...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Good Afternoon and welcome to HotCopper Highlights for Week 43, I’m Jon Davidson. In this segment the stocks you were watching and discussing the most this week, let’s get into it starting with the most viewed.  Pilbara Minerals has been...

Orthocell Ltd (ASX: OCC) shares are on course to end the week in the red. In morning trade, the ASX stock is down 7% to $1.33. However, longer term shareholders won't be too downbeat. That's because the regenerative medicine company's share...

ASX closes 0.86% higher to reach a new 100-day high after hitting an intraday record  Australia’s unemployment rate climbs to four-year high of 4.5% in September, up from revised 4.3% in August Rate sensitive sectors including real estate,...

Lynas Rare Earths Ltd (ASX: LYC) has been a star performer so far in 2025 with its share price soaring by 203% to $19.81 by Friday's close. The company operates the Mt Weld mine in Western Australia which is widely regarded as one of the...

ASX health sector moved up 1.30% for the week, while broader market inched up 0.12% This week: PainChek’s groundbreaking digital app scored coveted FDA De Novo clearance; The FDA lifted a clinical hold on Neurizon’s lead drug candidate for...

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 41 of the year, I’m Jon Davidson. In this segment the top stocks most watched and most discussed by you, HotCopper users, let’s get straight into it starting with the most...

Very few investors had heard of Dateline Resources Ltd (ASX: DTR) at the start of the year. In early January, shares in this ASX mining stock were changing hands at $0.003 per share, with its market capitalisation clocking in at less th...

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 9th of October. At least it was a green day! The XJO was tracking for a flattish green finish in the final moments of Thursday intraday trades. Materials was in the lead...

Welcome to this week’s HotCopper Wire, our market watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through the week’s biggest news headlines — and what they mean for Oz investors. In this Wee...

ASX gold shares are having an incredible run in 2025 amid the gold price soaring above US$4,000 per ounce for the first time overnight. At the time of writing, the gold price is US$4,011 per ounce, representing an astonishing 53% gain i...

Highlights Riversgold expands Kalgoorlie footprint Lithium Universe achieves solar recycling breakthrough Aurum Resources upgrades Boundiali project Explore recent developments in ASX mining stocks, gold exploration, and renewable...

ASX holds firm as oil spills, gold dips and tech sector surges Cannon-Brookes stirs up AGL climate clash DigiCo Eagers and Mesoblast fly high   By the close of Friday, the ASX’s 0.46% gain looked pretty darn respectable considering oil’s...

ASX heath sector up 2.84% for the week, while broader market rises ~2.4% Morgans Scott Power said sector showing signs of recovery heading into year end Race Oncology rises almost 30% this week after discovery in development of lead cardio...

Happy Friday, and welcome to HotCopper Highlights for Week 40 – I’m Isaac McIntyre, covering for Jonathon Davison while he’s off celebrating his birthday. In this segment, we’ll be looking at all the most popular stocks on Australia’s #1 fi...

Host Tylah Tully sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug. Tillett explains how understanding the drug’s mechanism increases the...

Race identifies primary mechanism of action for (E,E)-bisantrene (RCDS1), the active compound underpinning its lead candidate RC220 drug Targeting G4-DNA and RNA structures by RCDS1 reduces the activity of many important cancer genes, incl...

After five months of consecutive gains, the ASX 200 fell 0.78% in September with nine of 11 sectors in the red Smaller companies performed strongly with the ASX Emerging Companies and ASX Small Ordinaries rising 13% and 3% respectively Emb...

ASX goes on the offence, up 1.13pc 8 of 11 sectors higher, led by healthcare and materials Strength in resources, banks and healthcare drive gains   ASX roars higher, rotating back out of defensive sectors After playing it safe yesterday,...

The S&P/ASX 200 Index (ASX: XJO) is climbing higher today, up 1.27% at the time of writing. For the year, it is 9.27% higher. It's decent growth for the past 12-month period, but there is one stock that has far outpaced the index and...

Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-q...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

The S&P/ASX 200 Index (ASX: XJO) is back on form and racing higher on Thursday. In afternoon trade, the benchmark index is up 1.05% to 8,939.4 points. Four ASX shares that are rising more than most today are listed below. Here's why t...

Superannuation fund research house Chantwest has teamed up with retirement educator Bec Wilson on a new rating – the Epic Retirement Tick – and the bad news is only six out of Australia's more than 60 super funds have made the grade....

Race Oncology Ltd (ASX: RAC) shares have opened more than 20% higher after the company released positive cancer research data. The company's stock reached $3.74 in early trading, up 20.2%, marking a new high for the year and a three-year...

At the time of writing, there are roughly 380 ASX ETFs for investors to choose from.  However, in recent years, there has been more and more with more specific themes like AI, tech, or sustainability. Other times, new ETFs come...

Race Oncology (ASX:RAC) has announced the discovery of the primary mechanism of action of its lead anticancer candidate, (E,E)-bisantrene (RCDS1). Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest h...

Australian shares are heading towards a +0.5% jump at open, with Aussie traders unable to ignore the three-day rally Wall Street has been tearing through in Week 40 – and it’s even enough to beat the RBA hangover. Listen to the HotCopper...

Good afternoon, and welcome to the HotCopper HotList Top 10. Every week, hundreds of companies go through the ups and downs of the ASX trading rollercoaster, with fortunes made and equity lost each time the Aussie bourse opens – which is wh...

A happy Friday to you and welcome to HotCopper Highlights for Week 39 of the year, I’m Jon Davidson. In this segment we look at the most popular stocks on Australia’s #1 finance and stock research website, which means which stocks you were...

Every investor dreams of finding the next ASX stock that can turn a modest investment into a small fortune. While there are no guarantees in the market, history shows that some businesses do manage to grow far beyond expectations. With that...

Good Afternoon and welcome to HotCopper’s Market Close, I’m Jon Davidson – note today’s Close is an article only. What a day! We’re on the cusp of Week 40 of 2025 and it’s looking like a return to 9,000pts will probably be a thing of the Sa...

Deterra Royalties Ltd (ASX: DRR) shares are tumbling on Thursday. In afternoon trade, the ASX 200 mining stock is down over 6% to $3.92. This means the mining royalties company's shares have given back yesterday's gains and more. Is this a...

Highlights Yandal Resources Ltd (YRL) has expanded its Arrakis gold discovery by 400 metres, confirming a continuous mineralized system over a 2.2-kilometre trend. Race Oncology Ltd (RAC) has received approval from the Republic of Kore...

ASX falls 81 points or 0.92pc by end of trade Utilities and energy sectors the only resistance Financials hit hardest, undercut by inflation numbers ASX returns to September form The ASX 200 is in a snit once again, pulling sharply back i...